India Globalization Capital, Inc. (IGC) is comprised of two lines of business: an infrastructure operation and a plant and cannabinoid operation — both of which are industry authorities and pioneers. Our commitment to fostering partnerships allows us to execute powerful visions through innovation and dedication to excellence.
The depth of our team’s collective efforts is expansive, contracting infrastructure projects and renting equipment in India. We create and market new products and services, including but not limited to trading steel, iron ore and building materials in Hong Kong throughout South Asia. We provide premium customer service to the industries and businesses we serve.
We are leaders and visionaries in developing plant-based therapies that are rooted in hard science. Our second line of business, collectively, the “Plant- Based Therapy Business,” stems from plant extracts. Our plant-based products and therapies involve several brands that IGC develops and expects to commercialize.
IGC’s flagship, patent-pending product is Hyalolex™ — a plant-based based alternative therapy that is aimed at helping improve the quality of life for elderly patients suffering from dementia including Alzheimer’s disease (AD). Other alternative therapies in development include therapies for neuropathic pain, Parkinson’s disease (PD) and other Central Nervous System (CNS) disorders, among others. Hyalolex™ is based on a patent filing made by the University of South Florida for the treatment of AD. To learn more, visit us at IGC Pharma and Hyalolex.